SGHT
Sight Sciences, Inc.
NASDAQ · Healthcare · Medical - Devices · US
$8.30
−1.01%Aug 19, 2026, 11:05 UTC
The U.S. Food and Drug Administration updated the Indications for Use of Sight Sciences' TearCare System to include improvement of meibomian gland function in patients with evaporative dry eye disease, effective August 18, 2026.
Source:Aug 10, 2026, 00:00 UTC
Sight Sciences, Inc. appointed Kashif Rashid as Chief Legal Officer and Corporate Secretary, effective August 10, 2026, succeeding Jeremy Hayden, who departed from the role.
Aug 5, 2026, 20:05 UTC
Sight Sciences reported its financial results for the second quarter of 2026.
Aug 4, 2026, 21:37 UTC
Sight Sciences received FDA 510(k) clearance for its OMNI Ultra Surgical System, the first FDA-cleared MIGS device for single pass canaloplasty with TruSync Plus innovation.
Source: